3056105-63-3
Chemical Structure
OP-3136
- CAS No.: 3056105-63-3
- Formula:C20H22N4O7S
- Molecular Weight:462.48
InChIKey: KZSVPOQXJZQAQQ-UHFFFAOYSA-N
SMILES: COC1=CC(OC)=C(C(OC)=C1)S(=O)(NC(C2=NC(OC)=C(C=C2)CN3C=CC=N3)=O)=O
Biological Activity: OP-3136 is an orally active, highly selective inhibitor of KAT6A and KAT6B. OP-3136 inhibits the proliferation of prostate cancer, ovarian cancer and non-small cell lung cancer cells that express or overexpress KAT6A. OP-3136 reduces the proliferative capacity of cancer cells and suppresses cell growth in ER+ breast cancer cell models with KAT6 overexpression. OP-3136 induces tumor regression and inhibits tumor growth in an ovarian cancer xenograft model in immunodeficient mice. OP-3136 inhibits tumor growth in a non-small cell lung cancer xenograft model in immunodeficient mice. OP-3136 can be used in research related to HR+/HER2- breast cancer, prostate cancer, ovarian cancer and non-small cell lung cancer (NSCLC)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
OP-3136 | 99.90% | OP-3136 is an orally active, highly selective inhibitor of KAT6A and KAT6B. OP-3136 inhibits the proliferation of prostate cancer, ovarian cancer and non-small cell lung cancer cells that express or overexpress KAT6A. OP-3136 reduces the proliferative capacity of cancer cells and suppresses cell growth in ER+ breast cancer cell models with KAT6 overexpression. OP-3136 induces tumor regression and inhibits tumor growth in an ovarian cancer xenograft model in immunodeficient mice. OP-3136 inhibits tumor growth in a non-small cell lung cancer xenograft model in immunodeficient mice. OP-3136 can be used in research related to HR+/HER2- breast cancer, prostate cancer, ovarian cancer and non-small cell lung cancer (NSCLC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Gopinath S. Palanisamy, et al. Abstract LB166: OP-3136, a selective KAT6 inhibitor, demonstrates anti-tumor activity in prostate, ovarian, and non-small cell lung cancer preclinical models. Cancer Res (2025) 85 (8_Supplement_2): LB166.
- [2]. Roussel-Simonin C, et al. Exploring KAT6 as a therapeutic target in breast cancer: epigenetic approaches for precision medicine. NPJ Breast Cancer. 2025 Dec 19;11(1):146. [Content Brief]
Keywords
